Title: Daily Medi -- Biotechnology venture companies that may be the next Hanmi Pharm

Publication: Daily Medi/ Tae Hwan Kim

Date: 16 November 2015

Summary

• Three Korean biotechnology venture companies including LegoChem Biosciences are receiving attention to be the next Hanmi Pharm.

• LegoChem has originial ADC technology that is acclaimed for its innovative way to solve the common problem of the first generation ADC technology.

• LegoChem has already tranferred its technology to Fosun Pharma, a Chinese company, and is discussing the possibility of tranferring technology or collaborating research with various companies from the US, Europe, and Japan.

To view the full article (in Korean), click here ▶

About LegoChem Biosciences

LegoChem Biosciences, Inc. (LCB) is a research-based biotechnology company dedicated to discovering, developing, and commercializing innovative medicines by leveraging our chemistry expertise to make conventional biologics targeted and more potent for the benefit of patients with diseases of high unmet medical needs. We are advancing sustainable pipelines in therapeutic areas in antibiotics, anti-coagulants, oncology, antibody-drug conjugate (ADC), and protein-drug conjugate (PDC).